Does Antenatal MgSO₄ Administration to the Mother in the Event of Imminent Premature Birth Reduce the Occurrence of Infantile Cerebral Palsy in the Child? – An Umbrella Review

 

 Permissions and Reprints

Abstract

Introduction Premature births have a significantly increased risk of developing cerebral palsy. This clinical picture involves great restrictions and impairments in the lives of the children and their families. Its prevention is therefore of great importance. One method of neuroprotection to reduce the rate of infantile cerebral palsy is the antenatal administration of magnesium sulfate to the mother. The aim of this paper is to present the current state of research of existing reviews and meta-analyses on the topic and to review the evidence for this intervention.

Material and Methods A literature search was conducted within the framework of an umbrella review in the electronic database PubMed in February 2022 to identify all relevant publications on the topic. The search was structured using the PRISMA statement. The important methodological characteristics and the results of the studies were then extracted. In addition, a quality assessment of the studies was performed using the AMSTAR score.

Results Two systematic reviews with meta-analysis, one systematic review, and one individual participant data meta-analysis were included in this study. The total number of subjects was n = 6178. The publications conclude that the antenatal administration of magnesium sulfate to the mother significantly reduces the risk of cerebral palsy in preterm infants. Due to the high quality of 3 of the 4 studies, a high level of evidence can be assumed.

Conclusion The evidence for antenatal magnesium sulfate administration for the prophylaxis of cerebral palsy in preterm infants is high. However, further research is needed to determine which doses of magnesium and up to which gestational age the administration is useful.

Publication History

Received: 16 September 2022

Accepted after revision: 04 March 2023

Article published online:
04 May 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References/Literatur

• 1 World Health Organization. Preterm birth. 14.11.2022 Accessed January 26, 2023 at: https://www.who.int/news-room/fact-sheets/detail/preterm-birth
  PubMedGoogle Scholar
• 2 Vogel JP, Chawanpaiboon S, Moller AB. et al. The global epidemiology of preterm birth. Best Pract Res Clin Obstet Gynaecol 2018; 52: 3-12 DOI: 10.1016/j.bpobgyn.2018.04.003. (PMID: 29779863)
  CrossrefPubMedGoogle Scholar
• 3 Gesundheit in Deutschland. Gesundheitsberichterstattung des Bundes, gemeinsam getragen von RKI und Destatis. Lampert T, Prütz F, Seeling S, Starker A, Kroll LE, Rommel A, Ryl L, Ziese T. Berlin: Robert Koch-Institut; 2015
  Google Scholar
• 4 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V.. Prävention und Therapie der Frühgeburt. S2k-Leitlinie der DGGG, OEGGG und SGGG. 01.10.2022 Accessed January 26, 2023 at: https://register.awmf.org/assets/guidelines/015–025l_S2k_Praevention-Therapie-Fruehgeburt_2022–09.pdf
  PubMedGoogle Scholar
• 5 IQTIG – Institut für Qualitätssicherung und Transparenz im Gesundheitswesen.. Geburtshilfe. Bundesauswertung zum Erfassungsjahr 2017. Berlin: IQTIG; 2017
  Google Scholar
• 6 Oskoui M, Coutinho F, Dykeman J. et al. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol 2013; 55: 509-519 DOI: 10.1111/dmcn.12080. (PMID: 23346889)
  CrossrefPubMedGoogle Scholar
• 7 Durkin MS, Benedict RE, Christensen D. et al. Prevalence of Cerebral Palsy among 8-Year-Old Children in 2010 and Preliminary Evidence of Trends in Its Relationship to Low Birthweight. Paediatr Perinat Epidemiol 2016; 30: 496-510 DOI: 10.1111/ppe.12299.
  CrossrefPubMedGoogle Scholar
• 8 Statistisches Bundesamt. Gesundheit. Diagnosedaten der Patienten und Patientinnen in Krankenhäusern (einschl. Sterbe- und Stundenfälle). Wiesbaden: Destatis; 2017
  Google Scholar
• 9 Arnaud C, Ehlinger V, Delobel-Ayoub M. et al. Trends in Prevalence and Severity of Pre/Perinatal Cerebral Palsy Among Children Born Preterm From 2004 to 2010: A SCPE Collaboration Study. Front Neurol 2021; 12: 624884 DOI: 10.3389/fneur.2021.624884.
  CrossrefPubMedGoogle Scholar
• 10 Jahan I, Muhit M, Hardianto D. et al. Epidemiology of cerebral palsy in low- and middle-income countries: preliminary findings from an international multi-centre cerebral palsy register. Dev Med Child Neurol 2021; 63: 1327-1336 DOI: 10.1111/dmcn.14926.
  CrossrefPubMedGoogle Scholar
• 11 Dan B, Paneth N. Making sense of cerebral palsy prevalence in low-income countries. Lancet Glob Health 2017; 5: e1174-e1175 DOI: 10.1016/S2214-109X(17)30420-5. (PMID: 29102351)
  CrossrefPubMedGoogle Scholar
• 12 Graham HK, Rosenbaum P, Paneth N. et al. Cerebral palsy. Nat Rev Dis Primers 2016; 2: 15082 DOI: 10.1038/nrdp.2015.82. (PMID: 27188686)
  CrossrefPubMedGoogle Scholar
• 13 Genzel-Boroviczény O, Roos R. Checkliste Neonatologie. Stuttgart: Thieme; 2019
  Article in Thieme ConnectGoogle Scholar
• 14 Behrends JC, Bischofberger J, Deutzmann R, Ehmke H, Frings S, Grissmer S, Hoth M, Kurtz A, Leipziger J, Müller F, Pedain C, Rettig J, Wagner C, Wischmeyer E. Physiologie. Stuttgart: Thieme; 2017
  Article in Thieme ConnectGoogle Scholar
• 15 Gandor F. Neuroprotektive Effekte von Atorvastatin bei Glutamat-induzierter Exzitotoxizität in primären kortikalen Neuroronen [Dissertation]. Berlin: Freie Universität Berlin; 2010. DOI: 10.17169/refubium-16402
  CrossrefGoogle Scholar
• 16 Doyle LW, Crowther CA, Middleton P. et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; (01) CD004661 DOI: 10.1002/14651858.CD004661.pub3.
  CrossrefPubMedGoogle Scholar
• 17 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71 DOI: 10.1136/bmj.n71. (PMID: 33782057)
  CrossrefPubMedGoogle Scholar
• 18 Papatheodorou S. Umbrella reviews: what they are and why we need them. Eur J Epidemiol 2019; 34: 543-546 DOI: 10.1007/s10654-019-00505-6. (PMID: 30852716)
  CrossrefPubMedGoogle Scholar
• 19 Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid Based Ment Health 2018; 21: 95-100 DOI: 10.1136/ebmental-2018-300014. (PMID: 30006442)
  CrossrefPubMedGoogle Scholar
• 20 Shea BJ, Grimshaw JM, Wells GA. et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7: 10 DOI: 10.1186/1471-2288-7-10. (PMID: 17302989)
  CrossrefPubMedGoogle Scholar
• 21 Wolf HT, Huusom LD, Henriksen TB. et al. Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis. BJOG 2020; 127: 1180-1188 DOI: 10.1111/1471-0528.16238.
  CrossrefPubMedGoogle Scholar
• 22 Jacquemyn Y, Zecic A, van Laere D. et al. The use of intravenous magnesium in non-preeclamptic pregnant women: fetal/neonatal neuroprotection. Arch Gynecol Obstet 2015; 291: 969-975 DOI: 10.1007/s00404-014-3581-1.. (PMID: 25501980)
  CrossrefPubMedGoogle Scholar
• 23 Crowther CA, Middleton PF, Voysey M. et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Med 2017; 14: e1002398 DOI: 10.1371/journal.pmed.1002398. (PMID: 28976987)
  CrossrefPubMedGoogle Scholar
• 24 Mittendorf R, Dambrosia J, Pryde PG. et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002; 186: 1111-1118 DOI: 10.1067/mob.2002.123544.
  CrossrefPubMedGoogle Scholar
• 25 Crowther CA, Hiller JE, Doyle LW. et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290: 2669-2676 DOI: 10.1001/jama.290.20.2669.
  CrossrefPubMedGoogle Scholar
• 26 Marret S, Marpeau L, Zupan-Simunek V. et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*. BJOG 2007; 114: 310-318 DOI: 10.1111/j.1471-0528.2006.01162.x.
  CrossrefPubMedGoogle Scholar
• 27 Rouse DJ, Hirtz DG, Thom E. et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359: 895-905 DOI: 10.1056/nejmoa0801187. (PMID: 18753646)
  CrossrefPubMedGoogle Scholar
• 28 Duley L. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG 2007; 114: 300-309 DOI: 10.1111/j.1471-0528.2006.01166.x.
  CrossrefPubMedGoogle Scholar
• 29 Wolf HT, Brok J, Henriksen TB. et al. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG 2020; 127: 1217-1225 DOI: 10.1111/1471-0528.16239. (PMID: 32237024)
  CrossrefPubMedGoogle Scholar
• 30 American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol 2016; 128: e155-e164 DOI: 10.1097/AOG.0000000000001711. (PMID: 27661654)
  CrossrefPubMedGoogle Scholar
• 31 World Health Organization. WHO recommendations on interventions to improve preterm birth outcomes. Geneva: WHO; 2015
  Google Scholar
• 32 National Institute for Health and Care Excellence (NICE). Preterm labour and birth. NICE guideline. 20.11.2015 Accessed January 26, 2023 at: https://www.nice.org.uk/guidance/ng25/resources/preterm-labour-and-birth-pdf-1837333576645
  PubMedGoogle Scholar
• 33 Queensland Clinical Guideline. Preterm labour and birth. 01.12.2020 Accessed January 26, 2023 at: https://www.health.qld.gov.au/__data/assets/pdf_file/0019/140149/g-ptl.pdf
  PubMedGoogle Scholar
• 34 Crowther CA, Middleton PF, Wilkinson D. et al. Magnesium sulphate at 30 to 34 weeks’ gestational age: neuroprotection trial (MAGENTA)--study protocol. BMC Pregnancy Childbirth 2013; 13: 91 DOI: 10.1186/1471-2393-13-91. (PMID: 23570677)
  CrossrefPubMedGoogle Scholar
• 35 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V.. Hypertensive Schwangerschaftserkrankungen: Diagnostik und Therapie. S2k-Leitlinie der DGGG, OEGGG und SGGG. 01.05.2019 Accessed January 26, 2023 at: https://register.awmf.org/assets/guidelines/015–018l_S2k_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2019–07.pdf
  PubMedGoogle Scholar
• 36 Blauert C, Garnier Y, Berger R. Geburtshilfe. Neuroprotektion durch Magnesium – Ein Überblick. Geburtshilfe Frauenheilkd 2011; 71: 79-82 DOI: 10.1055/s-0030-1270881.
  Article in Thieme ConnectPubMedGoogle Scholar

• Supplementary Material